

Amendments to the Claims:

Please cancel claims 29-30 and add new claims 43-64. Further, please amend claims 28, 31, and 41 as follows. This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-3. (Canceled)

4. (Previously Presented) A compound selected from:

- 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
- 3-(1H-Tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole;
- 3-(1H-Tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole;
- 5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
- 5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
- 5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
- 5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
- 5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
- 5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;
- 5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole; and
- 5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole;

or a pharmaceutically acceptable salt, solvate or hydrate thereof.

5-6. (Canceled)

7. (Previously Presented) The compound according to claim 4 that is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

8-9. (Canceled)

10. (Previously Presented) The compound according to claim 4 that is 3-(1H-Tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
11. (Previously Presented) The compound according to claim 4 that is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 12-13. (Canceled)
14. (Previously Presented) The compound according to claim 4 that is 5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 15-16. (Canceled)
17. (Previously Presented) The compound according to claim 4 that is 5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
18. (Previously Presented) The compound according to claim 4 that is 5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
19. (Previously Presented) The compound according to claim 4 that is 5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
20. (Previously Presented) The compound according to claim 4 that is 5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.

21. (Previously Presented) The compound according to claim 4 that is 5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
22. (Previously Presented) The compound according to claim 4 that is 5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 23-25. (Canceled)
26. (Previously Presented) The compound according to claim 4 that is 5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole or a pharmaceutically acceptable salt, solvate or hydrate thereof.
27. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 4, or a pharmaceutically acceptable salt, solvate or hydrate thereof, in combination with a pharmaceutically acceptable carrier.
28. (Currently Amended) A method of ~~treatment of a metabolic related disorder~~ lowering triglycerides in an individual comprising administering to ~~an individual in need of such treatment~~ said individual a therapeutically-effective amount of a compound according to claim 4, or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 29-30. (Canceled)
31. (Currently Amended) A method of ~~raising HDL~~ lowering free fatty acids in an individual comprising administering to said individual a therapeutically-effective amount of a compound according to claim 4, or a pharmaceutically acceptable salt, solvate or hydrate thereof.
- 32-40. (Canceled)

41. (Currently amended) A method of producing a pharmaceutical composition comprising admixing a compound according to claim 4, or a pharmaceutically acceptable salt, solvate or hydrate thereof, with a pharmaceutically acceptable carrier.
42. (Canceled)
43. (New) The method according to claim 28, wherein said compound is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
44. (New) The method according to claim 28, wherein said compound is 3-(1H-Tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
45. (New) The method according to claim 28, wherein said compound is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
46. (New) The method according to claim 28, wherein said compound is 5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
47. (New) The method according to claim 28, wherein said compound is 5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
48. (New) The method according to claim 28, wherein said compound is 5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
49. (New) The method according to claim 28, wherein said compound is 5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.

50. (New) The method according to claim 28, wherein said compound is 5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
51. (New) The method according to claim 28, wherein said compound is 5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
52. (New) The method according to claim 28, wherein said compound is 5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
53. (New) The method according to claim 28, wherein said compound is 5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
54. (New) The method according to claim 31, wherein said compound is 3-(1H-Tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
55. (New) The method according to claim 31, wherein said compound is 3-(1H-Tetrazol-5-yl)-2,4-dihydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
56. (New) The method according to claim 31, wherein said compound is 3-(1H-Tetrazol-5-yl)-2,6-dihydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
57. (New) The method according to claim 31, wherein said compound is 5-Butyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.

58. (New) The method according to claim 31, wherein said compound is 5-Propyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
59. (New) The method according to claim 31, wherein said compound is 5-Propoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
60. (New) The method according to claim 31, wherein said compound is 5-Cyclopentyl-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
61. (New) The method according to claim 31, wherein said compound is 5-Fluoro-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
62. (New) The method according to claim 31, wherein said compound is 5-Isobutoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
63. (New) The method according to claim 31, wherein said compound is 5-Butoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.
64. (New) The method according to claim 31, wherein said compound is 5-Ethoxy-3-(1H-tetrazol-5-yl)-2,4,5,6-tetrahydro-cyclopentapyrazole, or pharmaceutically acceptable salt, solvate or hydrate thereof.